bioRxiv · 10.1101/2021.03.03.433558
Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
Abstract
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs).1 Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access.2 Subunit vaccines based on recombinant proteins are suited for large-volume microbial manufacturing to yield billions of doses annually, minimizing their manufacturing costs.3 These types of vaccines are well-established, proven interventions with multiple safe and efficacious commercial examples.4-6 Many vaccine candidates of this type for SARS-CoV-2 rely on sequences containing the receptor-binding domain (RBD), which mediates viral entry to cells via ACE2.7,8 Here we report an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines. Antibodies raised against the engineered protein exhibited heterotypic binding to the RBD from two recently reported SARS-CoV-2 variants of concern (501Y.V1/V2). Presentation of the engineered RBD on a designed virus-like particle (VLP) also reduced weight loss in hamsters upon viral challenge.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Dalvie, N. C., Rodriguez-Aponte, S. A., Hartwell, B. L., Tostanoski, L. H., Biedermann, A. M., Crowell, L. E., Kaur, K., Kumru, O., Carter, L., Yu, J., Chang, A., McMahan, K., Courant, T., Lebas, C., Lemnios, A. A., Rodrigues, K. A., Silva, M., Johnston, R. S., Naranjo, C. A., Tracey, M. K., Brady, J. R., Whittaker, C. A., Yun, D., Kar, S., Porto, M., Lok, M., Andersen, H., Lewis, M. G., Love, K. R., Camp, D. L., Silverman, J. M., Kleanthous, H., Joshi, S. B., Volkin, D. B., Dubois, P. M., Collin, N., King, N. P., Barouch, D. H., Irvine, D. J., Love, J. C.. 2021-03-04. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters. https://doi.org/10.1101/2021.03.03.433558
Cite the original work for its findings. Save a collection to share your selection of sources.